Sort
261,768 grants matching “gene therapy”
Thioredoxin Inhibitor, PX-12, in Phase II Clinical Trial
$973,839Linda Pestano · Prolx Pharmaceuticals Corporation · R44 · FY2008 · CA
Boosting Innate Immunity Through HIF to Treat Antibiotic-Resistant Infections
$973,816Victor Nizet · University Of California, San Diego · R01 · FY2014 · AI
T-Cell Receptor Gene Therapy for Human Cancers-Cures
$973,782James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Identifying Inborn Genetic Susceptibility to Development of Cancer Metastasis
$973,774Sanford D Markowitz · Case Western Reserve University · R01 · FY2011 · CA
MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer
$973,698Robert C Bast · University Of Tx Md Anderson Can Ctr · U01 · FY2019 · CA
Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis
$973,558Buel Rodgers · Aavogen, Inc. · R44 · FY2023 · AG
Drug Development for Prostate Cancer and other Metastatic Processes
$973,508William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Role of 11q23 Chromosome Abnormalities in the Causation of Acute Leukemia
$973,478Carlo M Croce · Ohio State University · P01 · FY2010 · CA
Exploratory Clinical Study to Evaluate the Potential Bioactivity of CLBS14 in Patients with Coronary Microvascular Dysfunction
$973,475Douglas W Losordo · Lisata Therapeutics Inc · R44 · FY2018 · HL
Tissue Processing-Sequencing Facility
$973,474Cathy D Vocke · Division Of Basic Sciences - Nci · ZIC · FY2023 · CA
Next Generation Smart Nanoparticles
$973,458Jianghong Rao · Stanford University · U54 · FY2014 · CA
Cell Prep Core
$973,443John Wunderlich · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA
Cell Production Facility Core
$973,441Mark Dudley · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA
UNC and PERLEGEN, Inc
$973,439Gary A Churchill · Jackson Laboratory · P50 · FY2007 · GM
Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs
$973,429Roger L Kaspar · Transderm, Inc. · R44 · FY2012 · AR
NCMRR-DC Core Molecular & Functional Outcome Measures in Rehabilitation Medicine
$973,339Eric P Hoffman · Children'S Research Institute · R24 · FY2010 · HD
Autoimmunity: Mechanisms of Unresponsiveness
$973,295Stanford University · P01 · FY2004 · AI
Transcriptional condensates, epigenetic editing and Rett Syndrome
$973,050Rudolf Jaenisch · Whitehead Institute For Biomedical Res · R01 · FY2019 · MH
Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer
$973,003Christopher Emil Whitehead · Mekanistic Therapeutics, Llc · R44 · FY2020 · CA
Proteomic Predictors of Clinical Outcome of Targeted Therapies in Prostate Cancer
$972,978David B Agus · Stanford University · U54 · FY2007 · CA
High-throughput development and characterization of compact tools for transcriptional and chromatin perturbations
$972,736Lacramioara Bintu · Stanford University · R01 · FY2024 · HG
Genomics and Proteomics of Head and Neck Cancer
$972,669Carter Van Waes · National Institute On Deafness And Other Communication Disorders · ZIA · FY2020 · DC
NF-kappaB in pathogenesis and therapy of head and neck cancer
$972,669Carter Van Waes · National Institute On Deafness And Other Communication Disorders · ZIA · FY2020 · DC
Reversing Cellular immortality in cancer
$972,569Steven E Artandi · Stanford University · R35 · FY2016 · CA
Identification of Lethal Melanomas at the Time of Diagnosis
$972,565Nancy E Thomas · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA